Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan

Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2009, Pages 455-464

  Dingemanse, Jasper ^a   Halabi, Atef ^b   Van Giersbergen, Paul L M ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Clinical Research Services   (Germany)

Author keywords

Drug transporter proteins; Liver cirrhosis; Pharmacodynamics; Pharmacokinetics; Tezosentan

Indexed keywords

BILIRUBIN; ENDOTHELIN 1; PLACEBO; TEZOSENTAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA;

ADULT; BILIRUBIN; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLACEBOS; PYRIDINES; TETRAZOLES; VASODILATOR AGENTS;

EID: 63849162287     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330157     Document Type: Article

References (34)

1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.
2. Boss C., Bolli M., Weller T. Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications. Curr Med Chem. 2002; 9: 349-383.
3. ChannickRN, Sitbon O., BarstRJ, Manes A., Rubin LJ Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43: 62S - 67S.
4. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house ? Br J Pharmacol. 2008; 153: 1105-1119.
5. Lalich M., McNeel DG, Wilding G., Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007; 25: 785-794.
6. Cahill PA, Redmond EM, Sitzmann JV Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther. 2001; 89: 273-293.
7. Sanyal AJ, Bosch J., Blei A., Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008; 134: 1715-1728.
8. Clozel M., Ramuz H., Clozel J-P., et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999; 290: 840-846.
9. Dingemanse J., Clozel M., van Giersbergen PLM. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol. 2002; 39: 795-802.
10. DingemanseJ., Clozel M., vanGiersbergen PLM. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol. 2002; 53: 355-362.
11. Treiber A., van Giersbergen PLM, Dingemanse J. In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans. Xenobiotica. 2003; 33: 399-414.
12. Van Giersbergen PLM, Dingemanse J. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan. Int J Clin Pharmacol Ther. 2003; 41: 261-266.
13. Cotter G., Kaluski E., Stangl K., et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail. 2004; 6: 601-609.
14. Brunner F., Bras-Silva C., Cerdeira AS, Leite-Moreira AF Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther. 2006; 111: 508-531.
15. Dingemanse J., Gunawardena KA, van Giersbergen PLM. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol. 2006; 61: 405-413.
16. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999; 37: 399-431.
17. Morgan DJ, McLean AJ Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet. 1995; 29: 370-391.
18. Dingemanse J., van Giersbergen PLM. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. Br J Clin Pharmacol. 2004; 57: 344-348.
19. Jedlitschky G., Hoffmann U., Kroemer HK Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. 2006; 2: 351-366.
20. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. http://www.fda.gov/cder/guidance.
21. van Giersbergen PLM, Wipfli P., Dingemanse J. Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2003; 792: 369-373.
22. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995; 29: 1039-1048.
23. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease ? Hepatology. 1991; 13: 786-795.
24. George J., Murray M., Byth K., Farrell GC Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995; 21: 120-128.
25. Elbekai RH, Korashy HM, El-Kadi AO The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004; 5: 157-167.
26. Ho RH, Kim RB Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005; 78: 260-277.
27. Faber KN, M1/4ller M., Jansen PL Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003; 55: 107-124.
28. Hooiveld GJ, van Montfoort JE, Meijer DKF, M1/4ller M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharmaceut Sci. 2001; 12: 525-543.
29. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005; 5: 987-994.
30. Van Giersbergen PLM, Bodin F., Dingemanse J. Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol. 2002; 58: 243-245.
31. Simonson SG, Martin PD, Mitchell P., Schneck DW, Lasseter KC, Warwick MJ Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol. 2003; 58: 669-675.
32. Yamashiro W., Maeda K., Hirouchi M., Adachi Y., Hu Z., Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006; 34: 1247-1254.
33. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997; 62: 272-278.
34. Wong F., Moore K., Dingemanse J., Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008; 47: 160-168.